Patents Assigned to Genomic Health, Inc.
  • Publication number: 20190256923
    Abstract: The present invention relates to biomarkers associated with breast cancer prognosis. These biomarkers include coding transcripts and their expression products, as well as non-coding transcripts, and are useful for predicting the likelihood of breast cancer recurrence in a breast cancer patient. The present invention also relates to a novel method of identifying intergenic sequences that correlate with a clinical outcome.
    Type: Application
    Filed: January 17, 2019
    Publication date: August 22, 2019
    Applicant: GENOMIC HEALTH, INC.
    Inventors: Joffre B. BAKER, Dominick SINICROPI, Robert J. PELHAM, Michael R. CRAGER, Francois COLLIN, James C. STEPHANS, Mei-Lan LIU, John D. MORLAN, Kunbin QU
  • Publication number: 20190249260
    Abstract: Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.
    Type: Application
    Filed: February 22, 2019
    Publication date: August 15, 2019
    Applicant: GENOMIC HEALTH, INC.
    Inventors: Steven SHAK, Frederick L. BAEHNER, Tara MADDALA, Mark LEE, Robert J. PELHAM, Wayne COWENS, Diana CHERBAVAZ, Michael C. KIEFER, Michael CRAGER, Audrey GODDARD, Joffre B. BAKER
  • Publication number: 20190241967
    Abstract: The present invention provides methods to determine the prognosis and appropriate treatment for patients diagnosed with cancer, based on the expression levels of one or more biomarkers. More particularly, the invention relates to the identification of genes, or sets of genes, able to distinguish breast cancer patients with a good clinical prognosis from those with a bad clinical prognosis. The invention further provides methods for providing a personalized genomics report for a cancer patient. The inventions also relates to computer systems and software for data analysis using the prognostic and statistical methods disclosed herein.
    Type: Application
    Filed: January 9, 2019
    Publication date: August 8, 2019
    Applicant: GENOMIC HEALTH, INC.
    Inventors: Joffre B. BAKER, Maureen T. CRONIN, Francois COLLIN, Mei-Lan LIU
  • Patent number: 10260104
    Abstract: The present disclosure includes assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for the patient, and likelihood that the patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: April 16, 2019
    Assignee: Genomic Health, Inc.
    Inventors: Steven Shak, Frederick L. Baehner, Tara Maddala, Mark Lee, Robert J. Pelham, Wayne Cowens, Diana Cherbavaz, Michael C. Kiefer, Michael Crager, Audrey Goddard, Joffre B. Baker
  • Publication number: 20190095575
    Abstract: The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The present invention also provides methods of obtaining a quantitative score for a patient with kidney cancer based on measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The genes may be grouped into functional gene subsets for calculating the quantitative score and the gene subsets may be weighted according to their contribution to cancer recurrence.
    Type: Application
    Filed: November 26, 2018
    Publication date: March 28, 2019
    Applicant: Genomic Health, Inc.
    Inventors: Steven SHAK, George Andrew WATSON, Michael R. CRAGER, Tara MADDALA, Margarita LOPATIN, Audrey GODDARD, Dejan KNEZEVIC, Christer SVEDMAN
  • Patent number: 10241114
    Abstract: The invention concerns sensitive methods to measure mRNA levels in biopsied tumor tissues, including archived paraffin-embedded biopsy material. The invention also concerns breast cancer gene sets important in the diagnosis and treatment of breast cancer, and methods for assigning the most optimal treatment options to breast cancer patient based upon knowledge derived from gene expression studies.
    Type: Grant
    Filed: June 9, 2006
    Date of Patent: March 26, 2019
    Assignee: Genomic Health, Inc.
    Inventors: Joffre B. Baker, Maureen T. Cronin, Michael C. Kiefer, Steve Shak, Michael Graham Walker
  • Patent number: 10179936
    Abstract: Algorithm-based molecular assays that involve measurement of expression levels of prognostic and/or predictive genes, or co-expressed genes thereof, from a biological sample obtained from a cancer patient, and analysis of the measured expression levels to provide information concerning the likelihood of recurrence of colorectal cancer and/or the likelihood of a beneficial response to chemotherapy for the patient are provided herein. Methods of analysis of gene expression values of prognostic and/or predictive genes, as well as methods of identifying gene expression-tumor region ratios, tumor-associated stromal surface area, and gene cliques, i.e. genes that co-express with a validated biomarker and thus may be substituted for that biomarker in an assay, are also provided.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: January 15, 2019
    Assignee: Genomic Health, Inc.
    Inventors: Steven Shak, Drew Watson, Xitong Li, Lawrence Lee, Kim Clark-Langone
  • Patent number: 10181008
    Abstract: The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The present invention also provides methods of obtaining a quantitative score for a patient with kidney cancer based on measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The genes may be grouped into functional gene subsets for calculating the quantitative score and the gene subsets may be weighted according to their contribution to cancer recurrence.
    Type: Grant
    Filed: May 29, 2014
    Date of Patent: January 15, 2019
    Assignee: Genomic Health, Inc.
    Inventors: Steven Shak, George Andrew Watson, Michael R. Crager, Tara Maddala, Margarita Lopatin, Audrey Goddard, Dejan Knezevic, Christer Svedman
  • Patent number: 10169530
    Abstract: The present invention relates to gene fusions and alternative spliced junctions associated with breast cancer. The present invention also relates to novel methods of identifying gene fusions and alternative spliced junctions in RNA sequencing data. The present invention further relates to predicting prognosis of a breast cancer patient based on the number of gene fusion events.
    Type: Grant
    Filed: November 4, 2013
    Date of Patent: January 1, 2019
    Assignee: Genomic Health, Inc.
    Inventors: Yan Ma, Kunbin Qu, Mei-Lan Liu, Ranjana Ambannavar, James Stephans
  • Publication number: 20180230548
    Abstract: The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of breast cancer.
    Type: Application
    Filed: February 15, 2018
    Publication date: August 16, 2018
    Applicant: Genomic Health, Inc.
    Inventors: Melody A. Cobleigh, Steven Shak, Joffre B. Baker, Maureen T. Cronin
  • Publication number: 20180208968
    Abstract: The invention relates to methods of depleting RNA from a nucleic acid sample. The RNA may be any RNA, including, but not limited to, rRNA, tRNA, and mRNA. The method is useful for depleting RNA from a nucleic acid sample obtained from a fixed paraffin-embedded tissue (FPET) sample. The method may also be used to prepare cDNA, in particular, a cDNA library for further analysis or manipulation.
    Type: Application
    Filed: January 10, 2018
    Publication date: July 26, 2018
    Applicant: Genomic Health, Inc.
    Inventors: Dominick Sinicropi, John Morlan
  • Patent number: 9944990
    Abstract: The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of breast cancer.
    Type: Grant
    Filed: April 21, 2014
    Date of Patent: April 17, 2018
    Assignee: GENOMIC HEALTH, INC.
    Inventors: Melody A. Cobleigh, Steven Shak, Joffre B. Baker, Maureen T. Cronin
  • Patent number: 9902991
    Abstract: The invention relates to methods of depleting RNA from a nucleic acid sample. The RNA may be any RNA, including, but not limited to, rRNA, tRNA, and mRNA. The method is useful for depleting RNA from a nucleic acid sample obtained from a fixed paraffin-embedded tissue (FPET) sample. The method may also be used to prepare cDNA, in particular, a cDNA library for further analysis or manipulation.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: February 27, 2018
    Assignee: GENOMIC HEALTH, INC.
    Inventors: Dominick Sinicropi, John Morlan
  • Publication number: 20180051348
    Abstract: The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of cancer, in particular of breast cancer.
    Type: Application
    Filed: August 11, 2017
    Publication date: February 22, 2018
    Applicants: Genomic Health, Inc., NSABP Foundation, Inc.
    Inventors: Joffre B. BAKER, John L. BRYANT, Soonmyung PAIK, Steven SHAK
  • Publication number: 20170211154
    Abstract: The present invention provides methods to determine the prognosis and appropriate treatment for patients diagnosed with cancer, based on the expression levels of one or more biomarkers. More particularly, the invention relates to the identification of genes, or sets of genes, able to distinguish breast cancer patients with a good clinical prognosis from those with a bad clinical prognosis. The invention further provides methods for providing a personalized genomics report for a cancer patient. The inventions also relates to computer systems and software for data analysis using the prognostic and statistical methods disclosed herein.
    Type: Application
    Filed: February 3, 2017
    Publication date: July 27, 2017
    Applicant: GENOMIC HEALTH, INC.
    Inventors: Joffre B. BAKER, Maureen T. CRONIN, Francois COLLIN, Mei-Lan LIU
  • Publication number: 20170121780
    Abstract: The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.
    Type: Application
    Filed: December 5, 2016
    Publication date: May 4, 2017
    Applicant: GENOMIC HEALTH, INC.
    Inventors: Wayne COWENS, Steven SHAK, Audrey GODDARD, Dejan KNEZEVIC, Joffre BAKER, Michael C. KIEFER, Tara MADDALA, Frederick L. BAEHNER
  • Patent number: 9605318
    Abstract: The present invention provides sets of genes the expression of which is important in the prognosis of cancer. In particular, the invention provides gene expression information useful for predicting whether cancer patients are likely to have a beneficial treatment response to chemotherapy FHIT; MTA1; ErbB4; FUS; BBC3; IGF1R; CD9; TP53BP1; MUC1; IGFBP5; rhoC; RALBP1; STAT3; ERK1; SGCB; DHPS; MGMT; CRIP2; ErbB3; RAP1GDS1; CCND1; PRKCD; Hepsin; AK055699; ZNF38; SEMA3F; COL1A1; BAG1; AKT1; COL1A2; Wnt.5a; PTPD1; RAB6C; GSTM1, BCL2, ESR1; or the corresponding expression product, is determined, said report includes a prediction that said subject has a decreased likelihood of response to chemotherapy.
    Type: Grant
    Filed: November 8, 2010
    Date of Patent: March 28, 2017
    Assignee: Genomic Health, Inc.
    Inventors: Joffre B. Baker, Steven Shak, Luca Gianni
  • Patent number: 9551034
    Abstract: The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.
    Type: Grant
    Filed: January 7, 2011
    Date of Patent: January 24, 2017
    Assignee: Genomic Health, Inc.
    Inventors: Wayne Cowens, Steven Shak, Audrey Goddard, Dejan Knezevic, Joffre Baker, Michael C. Kiefer, Tara Maddala, Frederick L. Baehner
  • Publication number: 20160222463
    Abstract: The present invention relates to biomarkers associated with breast cancer prognosis. These biomarkers include coding transcripts and their expression products, as well as non-coding transcripts, and are useful for predicting the likelihood of breast cancer recurrence in a breast cancer patient, The present invention also relates to a novel method of identifying intergenic sequences that correlate with a clinical outcome.
    Type: Application
    Filed: January 29, 2016
    Publication date: August 4, 2016
    Applicant: GENOMIC HEALTH, INC.
    Inventors: Joffre B. BAKER, Dominick S. SINICROPI, Robert J. PELHAM, Michael R. CRAGER, Francois COLLIN, James C. STEPHANS, Mei-Lan LIU, John D. MORLAN, Kunbin QU
  • Publication number: 20160097105
    Abstract: Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.
    Type: Application
    Filed: October 20, 2015
    Publication date: April 7, 2016
    Applicant: GENOMIC HEALTH, INC.
    Inventors: Steven SHAK, Frederick L. BAEHNER, Tara MADDALA, Mark LEE, Robert J. PELHAM, Wayne COWENS, Diana CHERBAVAZ, Michael C. KIEFER, Michael CRAGER, Audrey GODDARD, Joffre B. BAKER